Lidocaine ( DrugBank: Lidocaine )
12 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 3 |
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 22 | もやもや病 | 1 |
| 34 | 神経線維腫症 | 1 |
| 46 | 悪性関節リウマチ | 4 |
| 51 | 全身性強皮症 | 1 |
| 70 | 広範脊柱管狭窄症 | 1 |
| 86 | 肺動脈性肺高血圧症 | 1 |
| 107 | 若年性特発性関節炎 | 1 |
| 168 | エーラス・ダンロス症候群 | 2 |
| 226 | 間質性膀胱炎（ハンナ型） | 11 |
| 256 | 筋型糖原病 | 1 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02236260 (ClinicalTrials.gov) | September 3, 2014 | 29/8/2014 | Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation | Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders. | Parkinson's Disease | Procedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride) | Nantes University Hospital | NULL | Completed | 18 Years | 74 Years | All | 20 | N/A | France |
| 2 | JPRN-UMIN000009099 | 2012/10/01 | 12/10/2012 | The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormia | The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormia - The effect of lidocaine injection in Parkinson's disease patients with camptorcormia | Parkinson's disease | lidocaine injection into the external oblique normal saline injection into the external oblique | Parkinson's disease and Movement Disorder Center | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 10 | Not applicable | Japan |
| 3 | JPRN-UMIN000007617 | 2012/04/01 | 30/03/2012 | Effect of lidocaine injection for postural deformities in Parkinson's disease | Effect of lidocaine injection for postural deformities in Parkinson's disease - Lidocaine injection for postural deformities | Parkinson's disease | intramuscular injection of lidocaine | Dept. of Clinical pharmacology and Neurology, Ehime University | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00414453 (ClinicalTrials.gov) | January 2007 | 19/12/2006 | Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis | Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS) | Neuropathic Pain;Chronic Pain;Multiple Sclerosis | Drug: Lidocaine patch 5%;Drug: Extended-release oxycodone;Drug: Placebo extended-release oxycodone pills;Drug: Placebo lidocaine patches | University of Rochester | Endo Pharmaceuticals | Terminated | 18 Years | N/A | All | 19 | Phase 4 | United States |
22. もやもや病
臨床試験数 : 17 / 薬物数 : 22 - (DrugBank : 17) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100050015 | 2021-08-12 | 2021-08-15 | Effect of stellate ganglion block on intracranial vascular and stress level in patients with Moyamoya disease | Effect of stellate ganglion block on intracranial vascular and stress level in patients with Moyamoya disease | Moyamoya disease | stellate ganglion group:1.5% lidocaine planetary ganglion block; control group:DSA only, no stellate ganglion block; | the First Affiliated Hospital of Sun Yat-Sen University | NULL | Pending | 12 | 65 | Both | stellate ganglion group:12; control group:12; | China |
34. 神経線維腫症
臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03513757 (ClinicalTrials.gov) | March 4, 2018 | 4/2/2018 | Dexmedetomidine and Propofol for Pediatric MRI Sedation | An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging | Headache;Tumor;Seizure Disorder;Neurofibromatoses;Hydrocephalus;Abdominal Neoplasm;Spine Deformity | Drug: propofol;Drug: Dexmedetomidine;Drug: Glycopyrrolate;Drug: Lidocaine 1% Injectable Solution;Drug: Nitrous Oxide;Drug: Sevoflurane | Medical College of Wisconsin | NULL | Completed | 12 Months | 60 Months | All | 40 | Phase 4 | United States |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs041200048 | 02/10/2020 | 02/10/2020 | Certolizumab Pegol treatment with Reducing and stoppIng MEthotrexate in patients with Rheumatoid Arthritis in stable low disease activity-state | Certolizumab Pegol treatment with Reducing and stoppIng MEthotrexate in patients with Rheumatoid Arthritis in stable low disease activity-state - PRIMERA study | Rheumatoid arthritis | 1) MTX* - Continued group: Continued at a stable dose and interval throughout the cours of the study. Folic acid is continued if concomitantly used. - Withdrawn group: Week 0 to 12 Reduced after registration. The dose of MTX is reduced to half, regardless of the initial dose. Folic acid is continued if concomitantly used. Week 12 to 52 Discontinued if low disease activity was maintained. Folic acid is discontinued if concomitantly used. *The allowable range of adherence is -20% to +20%. 2) CZP and csDMARDs other than MTX Continued at a stable dose and interval throughout the course of the study in both groups. 3) Glucocorticoids Continued at a stable dose up to week 36, and allowedto taper after week 36 in both group. 4) Rescue treatment One or more of the following rescue treatments are performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request. - Restoring, restarting, or increasing doses of MTX - Increasing doses of or adding csDMARDs other than MTX. - Increasing doses of or adding glucocorticoids - Drainage of synovial fluid. - Administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine. | Asai Shuji | Kojima Toshihisa | Recruiting | >= 20age old | Not applicable | Both | 114 | N/A | Japan |
| 2 | ChiCTR2000033004 | 2020-06-01 | 2020-05-17 | Clinical study of intravenous lidocaine infusion in patients with rheumatoid arthritis | Clinical study of intravenous lidocaine infusion in patients with rheumatoid arthritis | Rheumatoid arthritis | Group 1:glucocorticoid;Group 2:intravenous lidocaine infusion and glucocorticoid;Group 3:intravenous lidocaine infusion;Group 4:NSAIDS; | Department of Pain, Guizhou Provincial People's Hospita | NULL | Pending | 18 | 65 | Both | Group 1:30;Group 2:30;Group 3:30;Group 4:30; | China | |
| 3 | JPRN-jRCT1041190125 | 09/03/2020 | 09/03/2020 | PRECIOUS-B study | Patient REported, Clinical, and Imaging OUtcomes of tapering methotrexate in patients with rheumatoid arthritis in Stable low disease activity with Baricitinib - PRECIOUS-B study | Rheumatoid arthritis | 1) MTX* Week 0 to 12 - Reduced after registration. - The dosing frequency of MTX is decreased from weekly to biweekly without a change in dose, regardless of the initial dose. - The dosing frequency of folic acid is decreased from weekly to biweekly without a change in dose if concomitantly used. Week 12 to 52 - Discontinued if low disease activity was maintained. - Folic acid is discontinued if concomitantly used. *The allowable range of adherence is -20% to +20%. 2) BAR - Continued at a stable dose and interval throughout the course of the study. 3) csDMARDs other than MTX - Continued at a stable dose and interval throughout the course of the study. 4) Glucocorticoids - Continued at a stable dose up to week 36, and allowed to taper after week 36. 5) Rescue treatments One or more of the following rescue treatments are performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request - Changing the dosing frequency back to weekly administration, restarting, or increasing doses of MTX. - Increasing doses of or adding csDMARDs other than MTX. - Increasing doses of or adding glucocorticoids. - Drainage of synovial fluid. - Administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine. | Asai Shuji | NULL | Recruiting | >= 20age old | Not applicable | Both | 51 | N/A | Japan |
| 4 | JPRN-jRCTs041180071 | 13/10/2016 | 07/03/2019 | T-ReX study | Tocilizumab treatment with Reducing and stopping methotreXate in patients with rheumatoid arthritis in stable low disease activity-state - T-ReX study | Rheumatoid arthritis | At week 0, the dosing frequency of MTX was decreased from weekly to biweekly without a change in dose, regardless of the initial dose. At week 12, MTX was discontinued if low disease activity was maintained. TCZ and csDMARDs other than MTX were continued at a stable dose and interval throughout the course of the study. Glucocorticoids were continued at a stable dose up to week 36, and allowed to taper after week 36. The use of oral analgesics (non-steroidal anti-inflammatory drugs, acetaminophen, pregabalin, and tramadol) was not prohibited during the study period. One or more of the following rescue treatments were performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request: changing the dosing frequency back to weekly administration, restarting, or increasing doses of MTX; increasing doses of or adding csDMARDs other than MTX or glucocorticoids; and administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine. | Kojima Toshihisa | NULL | Complete | >= 20age old | Not applicable | Both | 51 | N/A | Japan |
51. 全身性強皮症
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00740285 (ClinicalTrials.gov) | April 2004 | 19/8/2008 | Effectiveness and Safety of Lidocaine for Scleroderma | Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial | Scleroderma | Drug: Lidocaine 2% without vessel constrictor;Other: Placebo - physiological solution 0,9% | Federal University of São Paulo | NULL | Completed | 18 Years | 60 Years | Both | 26 | Phase 2/Phase 3 | Brazil |
70. 広範脊柱管狭窄症
臨床試験数 : 95 / 薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04992572 (ClinicalTrials.gov) | December 1, 2021 | 21/7/2021 | Study Comparing Local/ MAC Anesthesia in Lumbar Decompression | Randomized Study Comparing Local/ MAC Anesthesia to General for 1-3 Level Lumbar Decompressions | Lumbar Spinal Stenosis | Drug: Propofol Injection;Drug: Lidocaine Hydrochloride, Injectable | Stanford University | NULL | Recruiting | 40 Years | 95 Years | All | 100 | Early Phase 1 | United States |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01433328 (ClinicalTrials.gov) | January 2012 | 9/9/2011 | Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain | Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain | Pulmonary Arterial Hypertension | Drug: Lidocaine;Drug: Placebo | Jewish General Hospital | NULL | Terminated | 18 Years | 85 Years | All | 4 | Phase 4 | Canada |
107. 若年性特発性関節炎
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04775225 (ClinicalTrials.gov) | January 6, 2021 | 17/2/2021 | Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis | Hip Denervation in Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis;Hip Arthritis | Drug: Lidocaine;Drug: Placebo;Drug: Steroid | Sohag University | NULL | Completed | 2 Years | 18 Years | All | 120 | Phase 3 | Egypt |
168. エーラス・ダンロス症候群
臨床試験数 : 13 / 薬物数 : 21 - (DrugBank : 11) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05603741 (ClinicalTrials.gov) | November 10, 2022 | 24/10/2022 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2% | University of Calgary | Vanderbilt University Medical Center | Active, not recruiting | 18 Years | N/A | All | 155 | Phase 4 | Canada |
| 2 | NCT04036305 (ClinicalTrials.gov) | July 26, 2019 | 25/7/2019 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5% | Vanderbilt University Medical Center | University of Calgary | Enrolling by invitation | 18 Years | N/A | All | 230 | United States |
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05737121 (ClinicalTrials.gov) | March 7, 2023 | 10/2/2023 | Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: VNX001;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Vaneltix Pharma, Inc. | Prevail Infoworks, Inc | Not yet recruiting | 18 Years | N/A | All | 120 | Phase 2 | United States |
| 2 | NCT04401176 (ClinicalTrials.gov) | September 15, 2020 | 19/5/2020 | Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome | A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A | Walter Reed National Military Medical Center | NULL | Active, not recruiting | 18 Years | N/A | Female | 58 | Phase 2 | United States |
| 3 | NCT03844412 (ClinicalTrials.gov) | November 4, 2019 | 15/2/2019 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue Syndrome | Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pill | Duke University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 50 Years | Female | 400 | Phase 2 | United States |
| 4 | JPRN-UMIN000027918 | 2016/07/01 | 25/06/2017 | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis - Heparin-lidocaine intravesical injection therapy for interstitial cystitis | interstitial cystitis | heparin-lidocaine intravesical therapy | Department of Urology and Renal transplantation, Nagasaki University Hospital | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan |
| 5 | JPRN-UMIN000026714 | 2016/02/26 | 27/03/2017 | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. - RCT study of bladder instillation therapy for refractory interstitial cystitis. | Interstitial cystitis | Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. | Department of Urology, Mitsui Memorial Hospital | NULL | Pending | 20years-old | Not applicable | Male and Female | 20 | Phase 2,3 | Japan |
| 6 | NCT02591199 (ClinicalTrials.gov) | September 2015 | 28/10/2015 | Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Urigen | NULL | Terminated | 18 Years | N/A | All | 92 | Phase 2 | United States |
| 7 | NCT02517996 (ClinicalTrials.gov) | February 2015 | 23/2/2015 | Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial | Interstitial Cystitis;Painful Bladder Syndrome | Drug: Lidocaine;Drug: Placebo | Johns Hopkins University | NULL | Terminated | 18 Years | N/A | Female | 18 | N/A | United States |
| 8 | NCT01048177 (ClinicalTrials.gov) | December 2012 | 11/1/2010 | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | Vulvodynia | Drug: Bladder instillation with heparin/ lidocaine | Scripps Health | NULL | Withdrawn | 18 Years | 80 Years | Female | 0 | Phase 2 | United States |
| 9 | NCT01475253 (ClinicalTrials.gov) | November 2011 | 3/11/2011 | Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis | A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: Lidocaine Releasing Intravesical System - LiRIS®;Other: LiRIS Placebo;Procedure: Sham Cystoscopy Procedure | Allergan | TARIS Biomedical, Inc. | Terminated | 18 Years | N/A | Female | 104 | Phase 2 | United States;Canada |
| 10 | NCT00823030 (ClinicalTrials.gov) | January 2009 | 14/1/2009 | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Interstitial Cystitis | Procedure: Urodynamic study;Drug: Lidocaine;Other: Normal Saline | North Shore Long Island Jewish Health System | NULL | Withdrawn | 18 Years | 80 Years | Both | 0 | N/A | United States |
| 11 | NCT00256542 (ClinicalTrials.gov) | January 2006 | 17/11/2005 | Study of U101 for Bladder Pain and/or Urgency | A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin | Pelvic Pain;Interstitial Cystitis;Bladder Diseases | Drug: Alkalinized Lidocaine-Heparin | Urigen | NULL | Completed | 18 Years | N/A | Both | 90 | Phase 2 | United States |
256. 筋型糖原病
臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02240407 (ClinicalTrials.gov) | October 17, 2017 | 11/9/2014 | Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease | Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD) | Pompe Disease | Genetic: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase;Drug: Rapamycin;Other: saline;Drug: Rituxan;Drug: Diphenhydramine;Drug: Acetaminophen;Drug: Lidocaine;Drug: LMX 4 Topical Cream | University of Florida | NULL | Active, not recruiting | 18 Years | 50 Years | All | 2 | Phase 1 | United States |